Calcium

Change From Period Baseline in Chronic Pain Intensity on the Visual Analog Scale

Pain by visual analogue scale

To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26.

Annualised change in percentage plaque burden (Δ%PB)

Frequency of response

Percentage of participants meeting the multicomponent efficacy endpoint at Week 26

Change in AGEL Gamification Index (AGI) from Baseline to 12 Months

The proportion of patients who achieved biochemical control (serum phosphate above the lower limit of the local reference range) on a dose of less than 0.8 mg/kg per dose of Burosumab.

Change in functional capacity

Intelligence quotient

Intensity of post-operative pain

Incidence of dose-limiting toxicities (DLTs) (safety phase)

assess the clinical effectiveness of the locally delivered spirulina gel prepared by different pharmaceutical extraction methods as an adjunctive therapy to mechanical debridement in stage II grade B periodontitis.

Change in regional myocardial stunning.

Change in Frequency of Coronary Spasm Episodes

Number of Participants Consented

Change in sperm concentration (total count per ejaculate) at semen analysis (male subjects)

Proportion of participants with reported dose limiting toxicities (Phase 1)

Blood pressure

Clinical evaluation, Gait Analysis and Metabolic variables efficacy of therapy

Occurrence of target vessel revascularization, myocardial infarction and all-cause mortality

Lipid profile

Change in WHO Ordinal Scale for clinical improvement

Feasibility of the intervention - Number of completed tDCS applications

Incidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatment

Reaching 40 Patients

plasma concentration

Plasma levels of PPI

Questionnaires, self-reported changes in general physical health, and physiological measurements to predict of type of vaccine administered

Incidence and severity of adverse events (AEs) (CTCAE V5.0) over 22 days

Calcium

Glycemic index (HbA1c) levels

The prevalence and incidence rate of CAC in T2DM

Change in Minimal Fibrous Cap Thickness (FCT)

Objective Response Rate (ORR)

Efficacy of Acetazolamide on Ataxia Measured Via Miniature International Cooperative Ataxia Rating Scale (Mini-ICARS)

Recommended phase II dose (RP2D) of dasatinib

The rate of progression free patients at six months

Metabolic syndrome score

Determination of the efficacy of lenvatinib associated with denosumab in the treatment of patients with predominant bone metastases from Radioiodine-Refractory Differentiated Thyroid Carcinoma

Left Ventricular Mass

Incidence of a calcium score

Overall Survival (OS)

Catestatin levels in blood serum

Progression free survival (PFS)

Serum calcium

Prevalence of early heart failure in type 2 diabetes

Number of patients with decreased myocardial function assessed by echocardiography

changes in cardiovascular risk from baseline using the Framingham Coronary Heart Disease Score

Relationship between placental acute atherosis and subclinical coronary atherosclerosis at 1 year postpartum

Calcemia

Change in Resting Metabolic Rate

Change From Baseline at Week 40 in Serum Phosphorus

Estimation of the proportion of people in the Kalamazoo, MI, area who have asymptomatic CAD.

Maximum tolerated dose of carfilzomib with hyper-CVAD, defined as the dose that produces dose limiting toxicity in 17% or fewer (1/6) of patients, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4

Number of Patients Undergoing Surgical Resection After Receiving at Least 4 of the 6 Courses of Preoperative Chemotherapy

Major adverse cardiovascular outcome

PSA Response Rate

Incidence of adverse events assessed by CTCAE version 4.03

Arm A Only: Number of Participants With Progression-free Survival (PFS)

Percent Atheroma Volume (PAV)

Routine blood work and tumor markers

Number and severity of adverse events

myocardial injury reduction

Progression of contrast enhanced cardiac CT in relation to baseline and follow-up cardiovascular risk factors and biomarkers.

Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans

Progression free survival rate at 6 months

Overall Survival

Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests Indicated Below in Outcome Measure Description

Statin Prescription

A miRNA signature in the presence and absence of coronary artery calcification (CAC)

Calcium Score Measured from CT Angiography

Number of Participants With Pathological Complete Response (pCR) to Neoadjuvant Therapy

Maximum Tolerated Dose (MTD)

Percent Change From Baseline to Month 12 in Femoral BMD

Carotid artery cholesterol plaque regression and stabilization

determine DMO distal femur at 36 months

bone metabolism (bone mineral density and serum bone turnover biomarkers)

Percent Change From Baseline to Week 48 in Dual Energy X-ray Absorptiometry (DXA)-Measured BMD at the Spine for the Randomized Study Groups

Number of microcalcifications seen on MicroPure ultrasound

DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) Interim Maintenance High-dose Methotrexate Backbone

Change in the Numerical Pain Rating Scale

assess the mean fold increase in the number of peripheral CD34+ cells, at total daily doses ranging from 100mg to 400mgs over 1 to 28 days

Measure the Amount of Bone Mineral Density Loss in Non-metastatic Breast Cancer Patients Receiving a High Dose Vitamin D Therapy Along With a Structured Home-based Walking and Progressive Resistance Exercise Program.

Vitamin D Concentrations, Pre Operative and Post Bariatric Surgery Following 12 Weeks of Vitamin D Supplementation

Coronary Calcium Score

Maximum tolerated dose of yttrium-90 (90Y) M5A anti-CEA antibody when given in combination with FOLFIRI chemotherapy and bevacizumab

Remission of calciphylaxis skin lesions

To assess the safety of this regimen

Myocardial enzymes arise

Total Mortality

Facilitate translational and epidemiological research

Change in Rickets Severity on Skeletal Radiographs From Baseline to Week 24 as Measured by the Radiographic Global Impression of Change (RGI-C) Scale

Calcium in aortic valve and in coronary arteries assessed by multidetector CT scanner (Agatston units)

Number of Participants With Major Bleeding Events Adjudicated by Central Adjudication Committee

Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine

Change From Baseline in the Hamilton Depression Rating Scale (HAMD17), on Day 14 and 42

The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24.

Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)

Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event

Failure-free survival at 10 months

Incidence of vertebral fracture

Change of Cross-linked N-telopeptide of Type I Collagen (NTx) Level Assessed as Standardized Area Under the Curve From Screening to Month 12 in the Intent-to-Treat Population

Progression-free survival (PFS) in participants with advanced stage DLBCL

Change in carotid intima-media thickness

Efficacy parameter: use of calcium/calcitriol at 1 year post-transplantation.

Fibroglandular Tissue in Total Breast (FGBT%)

To compare % change in Lumbar Spine BMD from Baseline to Month 24 in ZOL (annual i.v. infusion) vs Alendronate (weekly oral) osteoporotic male populations

Primary outcome measures include - Coronary artery calcium (CAC) score at Year 4 - CAD risk factors, Framingham Risk Score (FRS), and health behaviors at Year 4 - Adverse cardiac outcomes during follow-up

Overall Response

BMD of the lumbar spine determined by a DEXA scan at 2 years